Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Liabilities (2016 - 2025)

Aptevo Therapeutics' Total Liabilities history spans 11 years, with the latest figure at $9.6 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 10.46% year-over-year to $9.6 million; the TTM value through Sep 2025 reached $9.6 million, down 10.46%, while the annual FY2024 figure was $10.8 million, 14.14% down from the prior year.
  • Total Liabilities for Q3 2025 was $9.6 million at Aptevo Therapeutics, up from $9.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $58.2 million in Q1 2021 and bottomed at $9.1 million in Q2 2025.
  • The 5-year median for Total Liabilities is $12.6 million (2023), against an average of $23.6 million.
  • The largest annual shift saw Total Liabilities surged 484.17% in 2021 before it plummeted 77.06% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $55.4 million in 2021, then plummeted by 70.68% to $16.2 million in 2022, then fell by 22.29% to $12.6 million in 2023, then dropped by 14.14% to $10.8 million in 2024, then decreased by 11.37% to $9.6 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Total Liabilities are $9.6 million (Q3 2025), $9.1 million (Q2 2025), and $9.8 million (Q1 2025).